Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

I have a PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL), Portugal. I did my post-doctoral research in Malaria with Prof. Maria Mota at Instituto de Medicina Molecular and Instituto Gulbenkian de Ciência for 6 years. Between 2009 and 2014, I have been a Staff Scientist (Programa Ciência 2008) in the T cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, where I continued studying malaria pathogenesis.

June 28, 2017July 1, 2017

Clinical Trial Evaluating Combination of Cabometyx, Tecentriq in Advanced Cancer Starting

News

A Phase 1 trial assessing the combination of Exelixis‘ Cabometyx (cabozantinib) and Genentech‘s Tecentriq (atezolizumab) in locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) is set to get ... Read more

May 30, 2017

Molecule Can Mask Cancer’s Pain, Helping the Disease Develop, Study Shows

News

The PD-L1 molecule can mask cancer’s pain, enabling malignancies to develop and spread without sending alarms to the immune system, according to a study. Researchers from Duke University School of ... Read more

December 3, 2015December 3, 2015

Novel Mechanism To Overcome Melanoma Resistance to Radiotherapy Revealed

News

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai revealed a new mechanism by which radiotherapy can successfully eradicate melanoma. These findings were published ... Read more

October 29, 2015October 30, 2015

FDA Approves Yervoy as Adjuvant Therapy for Resected Stage III Melanoma

News

The U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb‘s Yervoy (ipilimumab), 10 mg/kg, as an adjuvant therapy in patients with resectable Stage III cutaneous melanoma, making it the only immune checkpoint inhibitor approved by FDA for ... Read more

October 26, 2015October 27, 2015

Patrolling Monocytes Show Powerful Potential Against Lung Cancer Metastasis

News

A new study revealed patrolling monocytes, a subtype of white blood cells, directly control tumor metastasis to the lung in a living mouse model of cancer, a finding that could lead ... Read more

October 22, 2015October 22, 2015

Leukemic Cells Turned Into Cancer Killers via Agonist Antibody in New Study

News

Researchers at The Scripps Research Institute (TSRI) revealed a way to modify leukemia cells into leukemia-killing immune cells. This novel and surprising study may pave the way for the development ... Read more

July 9, 2015July 13, 2015

Lymphoma Escapes Immune Responses Via NKG2D Receptor Down-Regulation

News

Researchers from Helmholtz Zentrum München, Germany, revealed the mechanisms that inhibit natural killer (NK) cells and how this phenomenon can be overcomed in the context of malignant lymphoma. The study published ... Read more

July 9, 2015July 15, 2015

Clinical Trials Evaluate Novel Tumor Immunotherapies For Solid Tumors

News

Clinical trials are being conducted by Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) to evaluate Durvalumab, a checkpoint blockade antibody, alone and in combination with Tremelimumab, an ... Read more

May 19, 2015June 2, 2015

ISA’s Synthetic Long Peptide Immunotherapy Induced Regression of HPV 16-Associated Tumor

News

Research conducted by ISA Pharmaceuticals B.V. revealed a beneficial effect of Synthetic Long Peptide (SLP®) on intratumoral macrophages in cancer induced by human papilloma virus 16 (HPV16). The study entitled “Therapeutic ... Read more

April 23, 2015April 23, 2015

Pembrolizumab, a PD-1 inhibitor, Revealed as Promising Therapy for Malignant Pleural Mesothelioma

News

A new study showing that the PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, decreased the growth of tumors in 76% of individuals with pleural mesothelioma, a rare and fatal type ... Read more